Gi001

Phase 1

HHematology department of the 920th hospital

Gi001 is one of 15 therapeutic programs targeting B-cell Non Hodgkin Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-Cell Non Hodgkin LymphomaRecruiting

B-Cell Non Hodgkin LymphomaPhase 1

Recruiting

Competition

Competitive Landscape

18 competitors in B-Cell Non Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

5 2

Oncovin

Eli Lilly

Phase 2

1 3

Adriamycin

Pfizer

Phase 2

1 4

Rayos

RRoxane Laboratories

Phase 2

4 5

Cytoxan

BBaxter Healthcare Corporation

Phase 2

4 6

Surovatamig

AstraZeneca

Phase 2

2 7

Polivy

Roche

Phase 1

1 8

COLUMVI

Roche

Phase 1

1 9

LUNSUMIO

Roche

Phase 1

1 10

Gazyva

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

B-Cell Non Hodgkin Lymphoma

NCT07862010

Clinical

Trials by Indication[1]

B-cell Non Hodgkin Lymphoma1 trial

An Exploratory Clinical Study Evaluating GI001 in the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia

Recruiting·HHematology department of the 920th hospital·Phase 1·NCT07862010·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gi001. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Gi001. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hematology department of the 920th hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: HHematology department of the 920th hospital

Gi001

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

B-cell Non Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News